

Functions and Mechanisms of AKBA in Inflammation Diseases and Cancer

Qianqian Yin¹, Jing Bai¹, Yang Sun¹, Zhikai Wang¹ and Honglin Wang^{1*}

¹Shanghai Institute of Immunology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai 200025, China.

Received January 17, 2017; Accepted March 7, 2017; Published June 27, 2017

ABSTRACT

Bioactive molecules of traditional Chinese medicine have been gaining great momentum in the past few decades as treatments for many diseases. *Boswellia serrata*, via its active boswellic acids, appears to have promising anti-tumor and anti-inflammatory effects. Acetyl-11-Keto- β -Boswellic Acid (AKBA), is a major constituent and key bioactive molecule among boswellic acids. The potential roles of AKBA have been demonstrated in inflammatory diseases such as arthritis, inflammatory bowel disease, asthma and many types of tumors including glioma, leukemia, myeloma, pancreatic cancer, prostate cancer and other diseases. In this brief review, *in vitro* and *in vivo* functions of AKBA in inflammation diseases and tumors as well as the underlying mechanisms are discussed.

Keywords: AKBA, Boswellic acid, Inflammation, Cancer, Target

Abbreviations: AKBA: Acetyl-11-Keto- β -Boswellic Acid; IKK: I κ B kinase; Akt: Protein Kinase B; TNF- α : Tumor Necrosis Factor α ; NF- κ B: Nuclear Factor kappa-light-chain-enhancer of activated B cells; MCP-1: Monocyte Chemoattractant Protein 1; VEGF: Vascular Endothelial Growth Factor; MMP-3: Matrix Metalloproteinase-3; LTB₄: Leukotriene B₄; NASID: Nonsteroidal Anti-inflammatory Drug; LPS: Lipopolysaccharides; ROS: Reactive Oxygen Species; LDL: Low-density Lipoprotein; PGE₂: Prostaglandin E₂; PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase; COX: Cyclooxygenase; Erk: Extracellular Signal-Regulated Kinases; DR5: Death Receptor 5; CXCR: CXC Chemokine Receptors; CXCL: Chemokine (C-X-C motif) Ligand

INTRODUCTION

Boswellic acids are a series of pentacyclic triterpene molecules which exist in the *Boswellia* genus. Many researchers have demonstrated that Boswellic acids exert bioactivity both *in vitro* and *in vivo* as the main components of frankincense, which is traditionally used for treating arthritis and wound healing [1-4]. Boswellic acids have been revealed to act as anti-inflammatory and anti-tumor agents partially through inhibition of 5-lipoxygenase, topoisomerase and leukocyte elastase [5, 6] and other multiple mechanisms.

Among these Boswellic acids, AKBA is shown to be a major bioactive molecule displaying multiple functions in anti-inflammation and anti-tumor activity. Numerous studies focusing on AKBA have reported the beneficial and curative effects in treating inflammatory diseases and cancer. Published literature suggests that AKBA regulates a variety of molecular targets such as 5-lipoxygenase, NF- κ B, LL-37, HIF-1 and other molecules that contribute to inflammation and tumor progression [7-9]. In this review, the *in vitro* and *in vivo* activity of AKBA on several inflammatory diseases and cancer will be discussed. In addition, the putative and

possible mechanisms underlying this effective molecule may help tailor the future strategies for fighting against cancer and refractory inflammatory diseases.

Targets and Anti-inflammatory Mechanisms of AKBA

5-lipoxygenase

The resin of *Boswellia serrata* has been used in many countries as traditional medicine to treat inflammatory diseases. AKBA as one of the major constituents of

Corresponding author: Honglin Wang, Shanghai Institute of Immunology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai 200025, China, E-mail: honglin.wang@sjtu.edu.cn

Citation: Yin Q, Bai J, Sun Y, Wang and Wang H. (2017) Functions and Mechanisms of AKBA in Inflammation Diseases and Cancer. J Immunol Res Ther, 2(1): 81-89.

Copyright: ©2017 Yin Q, Bai J, Sun Y, Wang and Wang H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Boswellia serrata, has been proved to inhibit 5-lipoxygenase (5-LOX) *in vitro* and in animal models [6,10-15]. Leukotrienes has been implicated to have proinflammatory properties in inflammation and hypersensitivity [16,17]. 5-lipoxygenase, as a key enzyme in the leukotriene synthesis, has been developed to be a major target clinically [18]. 5-LOX product from exogenous arachidonic acid of rat peritoneal PMNL, was inhibited by 15 μ M AKBA. Natural and synthetic analogues of AKBA were tested for inhibiting 5-lipoxygenase in intact rat neutrophils [19]. Moreover, AKBA showed efficient inhibition of 5-lipoxygenase product formation in isolated human neutrophils with IC₅₀ of 2.8 to 8.8 μ M, while failed to inhibit that of human whole blood [20]. Upon noninhibitory pentacyclic triterpenes such as amyrin, 5-LOX product formation was reversed [21]. As for the underlying mechanism of binding, AKBA was shown to directly target 5-lipoxygenase via a pentacyclic triterpene-selective binding site [11,13]. These researches indicate that AKBA may be a potential drug for 5-lipoxygenase contributing inflammatory diseases.

Human leukocyte elastase

As is the case in many inflammatory diseases, levels of 5-LOX and elastase are increased simultaneously [22]. AKBA was reported to block the activity of human leukocyte elastase (HLE) in a dose-dependent manner *in vitro*, while other leukotriene biosynthesis inhibitors failed to inhibit HLE. In line with inhibition on 5-LOX, AKBA also exerts non-competitive mode of HLE blocking [5,10]. This unique dual inhibition of AKBA on both 5-LOX and HLE might provide us with better understanding about the pathophysiology of many inflammatory disease.

LL-37

LL-37, an antimicrobial peptide, also exerts immunomodulatory effects by induction of cytokines production of many immune and non-immune cells [23]. Macrophage-like cell lines produce TNF- α after LL-37 stimulation [24]. And mast cells release IL-2, IL-4 and IL-6 when stimulated with LL-37 [25]. As the sole member of cathelicidin with the immune modulating property, LL-37 contributes to many autoimmune disease development such as psoriasis, atherosclerosis, systemic lupus erythematosus and rheumatoid arthritis [26]. AKBA has been reported to directly bind to LL-37 using an unbiased target fishing approach and exert the inhibitory effect in a concentration dependent way [9]. Thus, AKBA may be a suitable and potential natural chemical to treat LL-37 associated diseases.

NF- κ B

NF- κ B, due to its controlling of many pro-inflammatory and cell proliferation associated genes transcription, is involved in a large number of diseases including inflammatory diseases and cancers. AKBA has been reported to be a natural inhibitor of NF- κ B in many studies through several different mechanisms. In PC-3 prostate cancer cells, AKBA was

shown to directly bind to IKK, subsequently inhibiting NF- κ B signaling pathway [27]. In accordance with this, AKBA was also reported to inhibit TNF- α induction by directly interaction with IKK and followed inhibition of NF- κ B in LPS-stimulated human monocytes [28]. AKBA potentiated apoptosis induced by TNF, suppressed TNF-induced invasion and inhibited NF- κ B ligand-induced osteoclastogenesis, all of which are considered to require NF- κ B activation. However, this inhibition on NF- κ B was not observed to act through direct binding to IKK, but through inhibition of Akt [29]. In the case of LPS-challenged ApoE^{-/-} mice, AKBA treatment significantly reduced NF- κ B activity and NF- κ B-dependent genes such as MCP-1, VEGF, IL-1 and TF, resulting in reduced atherosclerotic lesion size [30]. Targeting NF- κ B signaling, a pivotal cause in the pathogenesis of CD18hypo mouse model of psoriasis, with treatment of AKBA, NF- κ B-dependent cytokine production, intradermal MCP-1, IL-12 and IL-23 expression as well as the aberrant proliferation of keratinocytes were suppressed and reduced abundantly [31]. These reports indicate that AKBA, as a natural inhibitor of NF- κ B, may provide an effective tool for the treatment of many inflammatory diseases and cancers.

Potential Role of AKBA in Inflammatory Diseases

Arthritis

Osteoarthritis (OA) is the commonest form of inflammatory joint disease, characterized by articular cartilage degradation with an accompanying periarticular bone response [32]. Derivatives of boswellic acid have been demonstrated to suppress IL- β induced apoptosis of chondrocytes as well as TNF α induced production of MMP3 by synovial fibroblasts, thus demonstrated a clear therapeutic potential for the treatment of OA [33]. AKBA is a potent inhibitor of 5-lipoxygenase (5-LOX), an enzyme that catalyzes the generation of leukotrienes including LTB₄, which is a molecule strongly implicated in osteoarthritis (OA)-associated inflammation [34,35]. Huh Luo Xiao Ling Dan (HLXLD), a Chinese herbal formula containing AKBA has been traditionally used to treat arthritis and other chronic inflammatory diseases [36]. Boswellic acid is reported to attenuate mouse model of osteoarthritis either orally or topically treated [37]. Based on these, several drugs which mainly contain enriched AKBA, have been reported to have therapeutic effects on OA treatment. In a double-blind, randomized, placebo-controlled study, patients who received 5-Loxin (containing 30% enriched AKBA) treatment, showed significantly improvements in pain scores and physical function scores, accompanying reduced synovial fluid matrix metalloproteinase-3 comparing to placebo group [38]. Considering the poor bioavailability of AKBA by oral administration of 5-loxin, a novel *Boswellia serrata* extract Aflapin was developed [39], which contained at least 20% of AKBA. Compared with 5-Loxin, Aflapin treatment increased the availability of alba in systemic circulation of

experimental animals by 51.78%. Also, the inhibition of MMP-3 production was 14.83% better than 5-Loxin [33]. These investigations reveal that AKBA is potential and feasible to treat osteoarthritis as a alternative to NASID which exerts severe side effects such as stomach ulcers, heartburn, headaches, etc [40].

Atherosclerosis

Atherosclerosis is a inflammatory disease featured unresolved chronic inflammation condition [41]. During the inflammatory process of atherosclerosis, leukocyte adhesion and infiltration process lead to intimal arterial plaques formation, plaque rupture, thrombosis and finally occlusion [42]. NF- κ B plays an important role in all stages of atherogenesis through genes, membrane and cellular proteins, polypeptides, chemokines and hormonal influence [43]. In the animal experiment, atherosclerosis lesions were induced by LPS injection in ApoE^{-/-} mice. AKBA treatment reduced NF- κ B activity and subsequent NF- κ B-dependent genes expression such as MCP-1, MCP-3, MIP-2, VEGF and TF. Compared to LPS injection group, AKBA treated group exerted nearly 50% reduction of atherosclerotic lesion size. AKBA treatment did not affect the plasma concentration of triglycerides, total cholesterol, anti oxidized LDL antibodies and various subsets of lymphocyte-derived cytokines, indicating its non-toxicity and safety.

Inflammatory Bowel Disease

AKBA has been reported to attenuate indomethacin-induced ileitis, an experimental model of inflammatory bowel disease (IBD). Leukocyte-endothelial cell adhesive interactions and severe tissue injury were decreased with both low and high dose of AKBA treatment in a concentration-dependent manner [44]. A selective 5-LOX inhibitor, zileuton, was observed to significantly improve healing of dextran sodium sulphate-induced colitis rat model of IBD, through inhibition of neutrophil recruitment. This indicates that inhibitors of 5-LOX may play effective therapeutic role in treating chronic intestinal inflammation [45]. Sphingomyelin phosphodiesterase (SMase) is regarded to contribute to several inflammation-related diseases including IBD. As a specific inhibitor of 5-LOX, AKBA was found to inhibit and decrease SMase activity and expression in Caco-2 cells, resulting in inhibition of cell proliferation [46]. Besides its effectiveness, AKBA was test for its safety for influence on integrity and function of the intestinal epithelium. 0.027 μ g/ml of AKBA was administrated, and reduced NF- κ B phosphorylation as well as ROS increased by H₂O₂ exposure, which indicated the antioxidant activity and intestinal epithelium barrier protection from inflammatory damage of AKBA. All together, AKBA is a potential and safe natural product for treating intestinal inflammatory disease including IBD [47].

Psoriasis

Psoriasis is an immune-mediated, chronic inflammatory skin disease which affects about 2-4% of the western population [48]. It is featured by disfiguring erythematous skin lesions covered with white silvery scales and often leads to discrimination of the patients. The relapse and life-long accompany of this disease also result in substantial reduction in the life quality of the patients [49]. Thus, it is urgent to develop medicines that exert few side effects and significant therapeutic effects against psoriasis. In the CD18^{hypo} mouse model of psoriasis, systematically or locally treatment with AKBA was observed to profoundly suppress the NF- κ B signaling and the subsequent NF- κ B dependent TNF- α production by macrophages. In addition, administration of AKBA also attenuated the intradermal MCP-1, IL-12 and IL-23 expression level in previous skin lesions, which led to resolution of the abundant immune cell infiltrates and reduction of the aberrant proliferation of keratinocytes. All together, AKBA treatment largely improved the psoriasis disease activity score in the CD18^{hypo} mice with a nearly normal phenotype [31]. This finding demonstrates the mechanism which might underly the effectiveness of AKBA for psoriasis treatment.

Several drugs have been developed and even come onto market which containing AKBA as the main effective component, for the treatment of psoriasis as a complementary and alternative medicine. A phase III clinical trial of *Boswellia serrata* cream containing 5% of 95%AKBA revealed that 200 psoriasis patients enrolled showed marked improvement. A significant reduction in psoriasis activity severity index (PASI) score as well as biomarkers including TNF- α , VEGF, LTB4 and PGE2 were also observed [50].

Antitumor Effects

Anti-angiogenesis

Angiogenesis is essential for tumor growth and metastasis. There are a plenty of factors involving in the angiogenesis of tumor progression [51]. Fibroblast growth factors are a family of growth factors that are involved in many pathways that can contribute to carcinogenesis, and they also play a important role in angiogenesis. It has been reported that FGF acts synergistically with VEGF to promote angiogenesis and tumor maturation. Thus, targeting FGF is a potential strategy for inhibiting tumor angiogenesis [52]. AKBA was found to inhibit bFGF-induced angiogenesis in a Matrigel Plug Assay. Subcutaneous administration of AKBA for 10mg/kg/d inhibited Matrgel + bFGF-induced angiogenesis significantly comparing with indomethacin and cyclophosphamide at the same dose. Histological examination also revealed inhibition of blood vessels growth in comparison with the controlled group [7]. Besides, AKBA has also been reported to reduce and inhibit angiogenesis in prostate tumor growth and a mouse model of oxygen-induced retinopathy [53,54].

HIF-1

Hypoxia-inducible factor 1 (HIF-1), is a transcriptional activator that is highly involved in cancer pathogenesis and inflammatory disorders. Aberrant upregulation of HIF-1 is associated with aggressive tumor growth angiogenesis and metastasis, which makes it a feature of solid tumors [55]. Therefore, HIF-1 has been validated as a therapeutic target and inhibitors of HIF-1 have been considered to be a potential strategy against cancer [56]. In the screening of HIF-1 inhibitors from frankincense, molecularly imprinted polymer (MIP) was used. With quercetin, a known inhibitor of HIF-1, as the imprinted polymer, AKBA was then retained by solid phase extraction on MIP. AKBA effectively inhibited HIF-1 transcriptional activity and HIF-1 α induction at concentration larger than 10Mm [57].

mi-RNA

AKBA has been reported to modulate miRNAs both *in vitro* and *in vivo*. In HCT116, HT29, SW480, and SW620 CRC cell lines, expression levels of let-7 and miR-200 families, which are putative tumor-suppressive mi-RNAs, were significantly up-regulated when treated with AKBA. Downstream targets of let-7 and miR-200, such as *CDK6*, *vimentin* and *E-cadherin*, were subsequently regulated. As in the case of orthotopic CRC mouse model, the regulations of let-7, miR-200 and their target genes were identical with that *in vitro* [58]. In spite of let-7 and miR-200, AKBA has been reported to regulate miR-34a and miR-27a as well. In CRC cell lines including HCT116, RKO, SW480, SW620, HT29 and Caco2, AKBA inhibited cell proliferation, induced apoptosis and cell cycle arrest. Using gene expression array and *in-silico* analysis, miR-34a and miR-27a and their target genes were found to be regulated by AKBA. Furthermore, in a mouse xenograft model, AKBA showed tumor growth inhibition, which was consistent with *in vitro* findings [59]. These novel evidences of AKBA's anti-tumor effects via epigenetic machinery modulation provide a new insight into the application of AKBA.

Topoisomerase

In HL-60 AND CCRF-CEM cell lines, AKBA significantly reduced cell counts and thymidine incorporation in a concentration-dependent way, with its IC₅₀ being 30 μ M. Then, in a DNA relaxation assay, AKBA was found to inhibit topoisomerase I at the concentration of from 10 μ M, suggesting that induction of apoptosis in these two leukemia cell lines by AKBA may be due to inhibition of topoisomerase I [60].

AKBA has been reported as well to inhibit STAT-3 activation in human multiple myeloma cells [8].

AKBA Functions as an Anti-Tumor Agent**Glioma**

AKBA has been demonstrated to exert the cytotoxic effect against malignant glioma cell lines including both long-term and glioma initiating cell lines by inducing apoptosis at low concentrations with approximate EC₅₀ value being 20 μ M. This toxicity was obtained by inducing p53-dependent p21 expression, supporting by ectopic expression of p53. Nevertheless, treatment with AKBA of subtoxic concentration didn't interfere with the toxicity of other anti-cancer drugs toward glioma cells in acute cytotoxicity or clonogenic cell death assays. This indicates the effectiveness and safety of AKBA on human malignant glioma cells and makes AKBA a possible adjunct for the treatment of human malignant glioma [61]. In recent days, AKBA has been considered a useful adjunct agent for treating brain metastasis [62] and glioblastoma [63].

Colorectal cancer (CRC)

Colorectal cancer is the third most common cancer and the fourth most common cancer cause of death globally, accounting for roughly 1.2 million new cases and 600,000 deaths per year. The therapy for CRC patients with stage III/IV and high-risk stage II colon cancer are adjuvant chemotherapy [64]. AKBA has been reported to have chemoprevention effects on colorectal cancer both *in vitro* and *in vivo*. In the cases of CRC cell lines, AKBA induced HT-29 apoptosis slightly at the concentration of 30 μ M. It was observed that AKBA treated cells showed Akt activation by Ser473 and Thr308 phosphorylation. Inhibitors of PI3K pathway sharply enhanced AKBA induced HT-29 apoptosis, indicating that AKBA might induce CRC cell apoptosis through PI3K/Akt pathway [65]. Besides, AKBA was found to largely up-regulate let-7 and miR-200 expression in CRC cell lines, accompanied by modulated downstream target genes expression such as *CDK6*, *vimentin* and *E-cadherin*. This was supported by the orthotopic CRC mouse model where AKBA modulated downstream target genes of let-7 and miR-200, suggesting that AKBA might modulate epigenetic machinery to achieve its anti-cancer activity [58].

AKBA was also demonstrated to inhibit colorectal cancer progression or intestinal adenomatous polyposis in animal models. Orthotopic human CRC mouse model orally administrated with AKBA exhibited decreased tumor volumes without significant body weight loss compared to vehicle treated group. In addition, AKBA suppressed ascites and metastasis of tumors to the liver, lung and spleen. Biomarkers of tumor including Ki-67, CD31, NF- κ B, COX-2, cyclinD1, MMP-9 and VEGF were also inhibited by AKBA [66]. In *APC*^{min/+} mice which is another human CRC mouse model, gavage administration of AKBA decreased polyps by approximately 50% both in the small intestine and colon, along with prevention of malignant progression of these polyps [67]. There is considerable evidence that aspirin is potential for prevention of colorectal cancer. Also, broader clinical recommendations for aspirin-based

chemoprevention strategy have been recently established [68]. However, in the *APC^{min/+}* mouse model, AKBA exerted more potential prevention of small intestinal and colonic polyps than aspirin. And this efficacy of AKBA might contribute to its modulation of Wnt/ β -catenin and NF- κ B/COX-2 pathways [69].

Leukemia

AKBA has been reported to inhibit the proliferation and induce the apoptosis of several leukemia cell lines including HL-60 cells and CCRF-CEM cells [70-72]. DNA, RNA and protein synthesis were significantly inhibited by AKBA with IC₅₀ values of 0.6, 0.5 and 4.1 μ M respectively [70]. AKBA induced HL-60 and CCRF-CEM cells apoptosis in a dose-dependent manner, which might be due to topoisomerase I inhibition [60,73]. These suggest that AKBA might be a promising approach for acute myeloid leukemia, though still needs more investigations.

Hepatocellular carcinoma

In liver cancer HepG2 cells, AKBA decreased cell viability as well as [³H] thymidine incorporation, and strongly induced apoptosis accompanied by activation of caspase-3, caspase-8 and caspase-9 [74]. Dose-dependent increase in caspase-3 activity, TNF- α level and IL-6 level was observed in HepG2 cells. Besides, AKBA protected anti-cancer drug Doxorubicin induced hepatic toxicity in Wistar rats [75].

Meningioma

Meningioma cells established from surgically removed meningioma specimens, when treated with AKBA, exhibited decrease in viable cells and inhibition of Erk-1/2 pathway [76].

Prostate cancer

Prostate cancer is the most common malignancy in men and a major cause of cancer deaths contributing to 1-2% deaths in men [77]. Since reduction of androgen stimulation in prostatic cells is one of the main treatment strategies for prostate cancer and expensive drugs for this disease, new agents targeting this disease in a different mechanism are needed to be developed.

AKBA has been reported to inhibit chemoresistant androgen-independent PC-3 prostate cancer cells proliferation and elicit cell death *in vitro* by specifically inhibiting IKK activity and NF- κ B signaling pathway. Topical application of AKBA on PC-3 tumors xenograft and nude mice implanted with PC-3 tumors inhibited tumor growth without systemic toxicity [27]. As androgen receptor-mediated signaling is crucial for the progression and development of prostate cancer, AKBA was demonstrated to inhibit androgen receptor by interruption on Sp1 (specificity protein 1) binding activity in prostate cancer cells [78]. Sp1 was suggested to be a possible target for treatment of prostate cancer for use of natural and synthetic

compounds used to inhibit Sp1 in prostate cancer [79]. In addition, human prostate tumor xenograft mice treated with AKBA showed reduced tumor growth, which was well correlated with suppression of angiogenesis. *In vitro* experiment showed that AKBA inhibited VEGFR-2 phosphorylation and downstream protein kinases, indicating that AKBA might inhibit prostate tumor growth via intercepting VEGFR2 signaling pathway [53].

A novel mechanism of AKBA inhibition of prostate cancer cell lines was demonstrated as well. AKBA elicited apoptosis of LNCaP and PC-3 cells at concentrations above 10 μ g/ml. Caspase-8 was activated in AKBA treatment, which correlated with DR5 increase. Knocking down of DR5 by its shRNA inhibited AKBA-induced prostate cancer cell apoptosis and caspase-8 activation, suggesting that AKBA may induce apoptosis in prostate cancer cells through a DR-5-mediated pathway [80].

The anti-prostate cancer effect of AKBA through multiple targets and pathways demonstrates that AKBA has a large potential in strategies for treating prostate cancer.

Pancreatic cancer

Targeting CXCR4/CXCL12 pathway has been considered a promising strategy for treating tumor growth and metastasis of many types of cancers [81]. AKBA has been reported to suppress CXCR4 expression in PANC-28 cells *in vitro* and in orthotopic pancreatic cancer mouse model, with reduced tumor growth and metastasis [82,83]. Besides, pancreatic cancer cell lines including AsPC-1, PANC-28, MIA PaCa-2 cells proliferation were inhibited by AKBA treatment, which correlated with NF- κ B and its modulating target genes suppression. In the orthotopic human pancreatic animal model, AKBA also down-regulated Ki-67, CD31, COX-2, MMP-9 and VEGF expression [82].

CONCLUSIONS

This reviewed data suggest that AKBA can target and regulate multiple cell signaling pathways which contribute to the pathogenesis and development of inflammatory diseases and various types of tumors. These functions of AKBA make it a potential and useful natural molecule for treatment of many diseases including arthritis, inflammatory bowel disease, psoriasis, colorectal cancer, glioma, leukemia, prostate cancer and also as a alternative to NASID. In spite of the efforts that have been made through different methods including nanomicelles loaded with AKBA and transdermal microemulsions, there remains improvement for higher bioavailability of AKBA *in vivo*. Although the anti-inflammatory and anti-cancer effect of AKBA have been demonstrated *in vitro* and *in vivo*, resolving the problem of AKBA's bioavailability and enhancing its bioactivity in human patients will endow AKBA with more applications clinically in the future.

ACKNOWLEDGEMENT

This work is supported by grants from National Natural Science Foundation of China (Key Program, 31330026), National Natural Science Foundation of China (General Program, 31570922).

REFERENCES

- Ernst E (2008) Frankincense: systematic review.
- Ammon H (2010) Modulation of the immune system by *Boswellia serrata* extracts and boswellic acids. *Phytomedicine* 17: 862-867.
- Du Z, Liu Z, Ning Z, Liu Y, Song Z, et al. (2015) Prospects of boswellic acids as potential pharmaceuticals. *Planta Medica* 81: 259-271.
- Khan MA, Ali R, Parveen R, Najmi AK, Ahmad S (2016) Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from *Boswellia serrata*. *J Ethnopharmacol* 191: 315-323.
- Safayhi H, Rall B, Sailer ER, Ammon HPT (1997) Inhibition by Boswellic Acids of Human Leukocyte Elastase. *J Pharmacol Exp Ther* 281: 460-463.
- Wildfeuer A, Neu I, Safayhi H, Metzger G, Wehrmann M, et al. (1998) Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. *Arzneimittel-Forschung* 48: 668-674.
- Singh SK, Bhusari S, Singh R, Saxena A, Mondhe D, et al. (2007) Effect of acetyl 11-keto β -boswellic acid on metastatic growth factor responsible for angiogenesis. *Vascul Pharmacol* 46: 333-337.
- Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB (2009) Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. *Mol Cancer Res* 7: 118-128.
- Henkel A, Tausch L, Pillong M, Jauch J, Karas M, et al. (2015) Boswellic acids target the human immune system-modulating antimicrobial peptide LL-37. *Pharmacol Res* 102: 53-60.
- Rall B, Ammon HP, Safayhi H (1996) Boswellic acids and protease activities. *Phytomedicine* 3: 75-76.
- Safayhi H, Sailer E, Ammon H (1996) 5-Lipoxygenase inhibition by acetyl-11-keto- β -boswellic acid (AKBA) by a novel mechanism. *Phytomedicine* 3: 71-72.
- Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon H, et al. (1996) Acetyl-11-keto- β -boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. *Br J Pharmacol* 117: 615-618.
- Sailer ER, Schweizer S, Boden SE, Ammon H, Safayhi H (1998) Characterization of an acetyl-11-keto- β -boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. *Eur J Biochem* 256: 364-368.
- Poeckel D, Werz O (2006) Boswellic acids: biological actions and molecular targets. *Current medicinal chemistry* 13: 3359-3369.
- Vidal C, Gomez-Hernandez A, Sanchez-Galan E, Gonzalez A, Ortega L, et al. (2007) Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. *J Pharmacol Exp Ther* 320: 108-116.
- Di Gennaro A, Haeggström JZ (2012) The Leukotrienes: Immune-Modulating Lipid Mediators of Disease. *Adv Immunol* 116: 51.
- Di Gennaro A, Haeggström JZ (2014) Targeting leukotriene B4 in inflammation. *Expert Opin Ther Targets* 18: 79-93.
- Ford-Hutchinson AW, Gresser M, Young RN (1994) 5-Lipoxygenase. *Annu Rev Biochem* 63: 383-417.
- Sailer ER, Hoernlein RF, Ammon HP, Safayhi H (1996) Structure-activity relationships of the nonredox-type non-competitive leukotriene biosynthesis inhibitor acetyl-11-keto-beta-boswellic acid. *Phytomedicine* 3: 73-74.
- Siemoneit U, Pergola C, Jazzar B, Northoff H, Skarke C, et al. (2009) On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. *Eur J Pharmacol* 606: 246-254.
- Safayhi H, Sailer ER, Ammon HP (1995) Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. *Mol Pharmacol* 47: 1212-1216.
- Mayatepek E, Hoffmann GF (1995) Leukotrienes: biosynthesis, metabolism, and pathophysiologic significance. *Pediatric Res* 37: 1-9.
- Vandamme D, Landuyt B, Luyten W, Schoofs L (2012) A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol* 280: 22-35.
- Zughaiier SM, Shafer WM, Stephens DS (2005) Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. *Cell Microbiol* 7: 1251-1262.
- Niyonsaba F, Ushio H, Hara M, Yokoi H, Tomimaga M, et al. (2010) Antimicrobial peptides human β -defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. *J Immunol* 184: 3526-3534.

26. Kahlenberg JM, Kaplan MJ (2013) Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. *J Immunol* 191: 4895-4901.
27. Syrovets T, Gschwend JE, Büchele B, Laumonnier Y, Zugmaier W, et al. (2005) Inhibition of I κ B kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. *J Biol Chem* 280: 6170-6180.
28. Syrovets T, Büchele B, Krauss C, Laumonnier Y, Simmet T (2005) Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF- α induction in monocytes by direct interaction with I κ B kinases. *J Immunol* 174: 498-506.
29. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB (2006) Acetyl-11-keto- β -boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF- κ B and NF- κ B-regulated gene expression. *J Immunol* 176: 3127-3140.
30. Cuaz-Pérolin C, Billiet L, Baugé E, Copin C, Scott-Algara D, et al. (2008) Antiinflammatory and antiatherogenic effects of the NF- κ B inhibitor acetyl-11-keto- β -boswellic acid in LPS-challenged ApoE $^{-/-}$ mice. *Arterioscler Thromb Vasc Biol* 28: 272-277.
31. Wang H, Syrovets T, Kess D, Büchele B, Hainzl H, et al. (2009) Targeting NF- κ B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. *J Immunol* 183: 4755-4763.
32. Felson DT (2004) An update on the pathogenesis and epidemiology of osteoarthritis. *Radiologic Clinics* 42: 1-9.
33. Sengupta K, Kolla JN, Krishnaraju AV, Yalamanchili N, Rao CV, et al. (2011) Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel *Boswellia serrata* extract. *Mol Cell Biochem* 354: 189-197.
34. Lascelles BDX, King S, Roe S, Marcellin-Little DJ, Jones S (2009) Expression and activity of COX-1 and 2 and 5-LOX in joint tissues from dogs with naturally occurring coxofemoral joint osteoarthritis. *J Orthop Res* 27: 1204-1208.
35. Rzodkiewicz P, Gąsińska E, Gajewski M, Bujalska-Zadrożny M, Szukiewicz D, et al. (2016) Esculetin reduces leukotriene B4 level in plasma of rats with adjuvant-induced arthritis. *Reumatologia* 54: 161-164.
36. Wang H, Zhang C, Wu Y, Ai Y, Lee DYW, et al. (2014) Comparative pharmacokinetic study of two boswellic acids in normal and arthritic rat plasma after oral administration of *Boswellia serrata* extract or Huo Luo Xiao Ling Dan by LC-MS. *Biomed Chrom* 28: 1402-1408.
37. Wang Q, Pan X, Wong H, Wagner C, Lahey L, et al. (2014) Oral and topical boswellic acid attenuates mouse osteoarthritis. *Osteoarthr Cartil* 22: 128-132.
38. Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, et al. (2008) A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee. *Arthritis Res Ther* 10: 1.
39. Krishnaraju A, Sundararaju D, Vamsikrishna U, Suryachandra R, Machiraju G, et al. (2010) Safety and toxicological evaluation of Aflapin®: A novel *Boswellia*-derived anti-inflammatory product. *Toxicology Mech Meth* 20: 556-563.
40. Richette P, Latourte A, Frazier A (2015) Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend? *Expert Opin Drug Saf* 14: 1259-1268.
41. Viola J, Soehnlein O (2015) Atherosclerosis—a matter of unresolved inflammation. in *Seminars in immunology*. Elsevier.
42. Ross R (1999) Atherosclerosis—an inflammatory disease. *New Eng J Med* 340: 115-126.
43. Pateras I, Giaginis C, Tsigris C, Patsouris E, Theocharis S (2014) NF- κ B signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. *Exp Opinion Ther Targets* 18: 1089-1101.
44. [44] Krieglstein, C.F., C. Anthoni, E.J. Rijcken, M. Laukötter, H.-U. Spiegel, et al. (2001) Acetyl-11-keto- β -boswellic acid, a constituent of a herbal medicine from *Boswellia serrata* resin, attenuates experimental ileitis. *Int J Colorectal Dis* 16: 88-95.
45. Singh VP, Patil CS, Kulkarni SK (2004) Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats. *Indian J Exp Biol* 42: 667-673.
46. Zhang Y, Duan RD (2009) Boswellic acid inhibits expression of acid sphingomyelinase in intestinal cells. *Lipids Health Dis* 8: 1.
47. Catanzaro D, Rancan S, Orso G, Dall'Acqua S, Brun P, et al. (2015) *Boswellia serrata* preserves intestinal epithelial barrier from oxidative and inflammatory damage. *PloS one* 10: e0125375.
48. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *J Invest Dermatol* 133: 377-385.
49. Schön MP, Boehncke WH (2005) Psoriasis. *New Eng J Med* 352: 1899-1912.
50. Majeed Muhammed KN, Sankaran N, Sood R, Karri SK (2014) Clinical evaluation of AKBBA in the management of psoriasis. *Clin Dermatol* 2: 17-24.

51. Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. *Nature Med* 17: 1359-1370.
52. Lieu C, Heymach J, Overman M, Tran H, Kopetz S (2011) Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. *Clin Cancer Res* 17: 6130-6139.
53. Pang X, Yi Z, Zhang X, Sung B, Qu W, et al. (2009) Acetyl-11-keto- β -boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. *Cancer Res* 69: 5893-5900.
54. Lulli M, Cammalleri M, Fornaciari I, Casini G, Dal Monte M (2015) Acetyl-11-keto- β -boswellic acid reduces retinal angiogenesis in a mouse model of oxygen-induced retinopathy. *Exp Eye Res* 135: 67-80.
55. Park JW, Chun YS, Kim MS (2004) Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. *J Pharmacol Sci* 94: 221-232.
56. Belozero V, Van Meir EG (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. *Anticancer Drugs* 16: 901.
57. Lakka A, Mylonis I, Bonanou S, Simos G, Tsakalof A (2011) Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer. *Invest New Drugs* 29: 1081-1089.
58. Takahashi M, Sung B, Shen Y, Hur K, Link A, et al. (2012) Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. *Carcinogenesis* 33: 2441-2449.
59. Toden S, Okugawa Y, Buhrmann C, Nattamai D, Anguiano E, et al. (2015) Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. *Cancer Prev Res* 8: 431-443.
60. Hoernlein R, Orlikowsky T, Zehrer C, Niethammer D, Sailer E, et al. (1999) Acetyl-11-keto- β -boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. *J Pharmacol Exp Ther* 288: 613-619.
61. Glaser T, Winter S, Groscurth P, Safayhi H, Sailer E, et al. (1999) Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. *Br J Cancer* 80: 756.
62. Kirste S, Treier M, Wehrle SJ, Becker G, Abdel-Tawab M, et al. (2011) Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors. *Cancer* 117: 3788-3795.
63. Schneider H, Weller M (2016) Boswellic acid activity against glioblastoma stem-like cells. *Oncol Lett* 11: 4187-4192.
64. Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. *The Lancet* 383: 1490-1502.
65. Liu JJ, Duan RD (2009) LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells. *Anticancer Res* 29: 2987-2991.
66. Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, et al. (2012) Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. *Int J Cancer* 130: 2176-2184.
67. Liu HP, Gao ZH, Cui SX, Wang Y, Li BY, et al. (2013) Chemoprevention of intestinal adenomatous polyposis by acetyl-11-keto-beta-boswellic acid in APCMin/+ mice. *Int J Cancer* 132: 2667-2681.
68. Drew DA, Cao Y, Chan AT (2016) Aspirin and colorectal cancer: the promise of precision chemoprevention. *Nat Rev Cancer*.
69. Wang R, Wang Y, Gao Z, Qu X (2014) The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC Min/+ mice. *Drug Discov Ther* 8: 25-32.
70. Shao Y, Ho CT, Chin CK, Badmaev V, Ma W, et al. (1998) Inhibitory activity of boswellic acids from *Boswellia serrata* against human leukemia HL-60 cells in culture. *Planta Medica* 64: 328-331.
71. Huang MT, Badmaev V, Ding Y, Liu Y, Xie JG, et al. (2000) Anti-tumor and anti-carcinogenic activities of triterpenoid, β -boswellic acid. *Biofactors* 13: 225-230.
72. Hostanska K, Daum G, Saller R (2001) Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro. *Anticancer Res* 22: 2853-2862.
73. Yuan X, Li Y, Qi Z, Peng M, Wan Z, et al. (2010) Effect of acetyl-11-keto- β -boswellic acid on proliferation, apoptosis and cell cycle of human acute myeloid leukemia cell line HL-60. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 18: 1440-1444.
74. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Duan RD (2002) Keto-and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. *Int J Mol Med* 10: 501-505.
75. Khan MA, Singh M, Khan MS, Najmi AK, Ahmad S (2014) Caspase mediated synergistic effect of *Boswellia serrata* extract in combination with doxorubicin against human hepatocellular carcinoma. *BioMed Res Int*.
76. Park YS, Lee JH, Bondar J, Harwalkar JA, Safayhi H, et al. (2002) Cytotoxic action of acetyl-11-keto-beta-boswellic acid (AKBA) on meningioma cells. *Planta Med* 68: 397-401.

77. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, et al. (2016) Prostate cancer. *The Lancet* 387: 70-82.
78. Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, et al. (2008) Inhibitory effect of acetyl-11-keto- β -boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. *Biochem Pharmacol* 75: 2112-2121.
79. Sankpal UT, Goodison S, Abdelrahim M, Basha R (2011) Targeting SP1 transcription factor in prostate cancer therapy. *Med Chem* 7: 518-525.
80. Lu M, Xia L, Hua H, Jing Y (2008) Acetyl-Keto- β -Boswellic Acid Induces Apoptosis through a Death Receptor 5-Mediated Pathway in Prostate Cancer Cells. *Cancer Res* 68: 1180-1186.
81. Guo F, Wang Y, Liu J, Mok S, Xue F, et al. (2015) CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. *Oncogene*.
82. Park B, Prasad S, Yadav V, Sung B, Aggarwal BB (2011) Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. *PLoS One* 6: e26943.
83. Park B, Sung B, Yadav VR, Cho SG, Liu M, et al. (2011) Acetyl-11-keto- β -boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. *Int J Cancer* 129: 23-33.